|Year : 2016 | Volume
| Issue : 2 | Page : 331
Maxillofacial esthesioneuroblastoma: A diagnostic complexity
G Shyam Raj, Guttikonda Venkateswara Rao, Manchikatla Praveen Kumar, Kondamari Sudheerkanth
Department of Oral Pathology and Microbiology, Mamata Dental College, Khammam, Telangana, India
|Date of Submission||29-Oct-2015|
|Date of Acceptance||22-May-2016|
|Date of Web Publication||11-Jul-2016|
G Shyam Raj
Department of Oral Pathology and Microbiology, Mamata Dental College, Giri Prasad Nagar, Khammam - 507 002, Telangana
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Esthesioneuroblastoma is a rare malignant tumor of the sinonasal tract. Oral and maxillofacial pathologists rarely encounter this tumor in their daily practice. Because of their complex anatomic location, non-specific symptoms, varied histomorphology and unfamiliarity, most of the times, the tumor is diagnosed as benign tumor and thereby conservative treatment results in multiple recurrences. A recurrent case of esthesioneuroblastoma in a 24-year-old female patient describing the clinical, histopathological and immunohistochemical features along with differential diagnosis is discussed.
Keywords: Esthesioneuroblastoma, olfactory neuroblastoma, sinonasal tract
|How to cite this article:|
Raj G S, Rao GV, Kumar MP, Sudheerkanth K. Maxillofacial esthesioneuroblastoma: A diagnostic complexity. J Oral Maxillofac Pathol 2016;20:331
|How to cite this URL:|
Raj G S, Rao GV, Kumar MP, Sudheerkanth K. Maxillofacial esthesioneuroblastoma: A diagnostic complexity. J Oral Maxillofac Pathol [serial online] 2016 [cited 2021 Feb 27];20:331. Available from: https://www.jomfp.in/text.asp?2016/20/2/331/185922
| Introduction|| |
Esthesioneuroblastoma also called olfactory neuroblastoma is a rare malignant neuroectodermal tumor of the sinonasal tract region, first described by Berger et al. in 1924. According to the World Health Organization, olfactory neuroblastoma is defined as a “malignant neuroectodermal tumor, that is, assumed to originate from olfactory receptor cells present high in the nasal cavity.” This justifies the most common site of the tumor being cribriform plate, middle superior nasal structures and anterior skull base.,
It accounts to about 3–6% of all sinonasal malignancies. These tumors show varied morphology with uncertain histogenesis which results in two extremes, i.e. an indolent growth with more than 20-year survival or an aggressive tumor with limited survival and distant metastasis.
Most of the pathologists encounter difficulties in the diagnosis of these malignancies because of their complex anatomic location, non-specific symptoms, variable morphology and unfamiliarity which leads to misdiagnosis as benign tumors. A case of aggressive olfactory neuroblastoma, which recurred thrice following complete surgical excision, is reported.
| Case Report|| |
A 24-year-old female patient reported to the Outpatient Department of our hospital complaining of swelling associated with pain on the left side of the face since 1 month. Initially the swelling was about peanut size, which gradually increased to present size, and was associated with pricking and localized pain. Medical history revealed blurred vision and lacrimation for the past 1 week. Her dental history revealed surgical excision of a tumor in 2007 and subsequent recurrent lesion at the same site in 2013 which was again operated.
At present, extra-oral examination revealed a solitary diffuse swelling in the left infraorbital region of the face measuring approximately 4 cm × 4 cm, extending mediolaterally from the medial canthus of the eye to frontozygomatic region and superioinferiorly from the lower eyelid to 1 cm above the left corner of mouth obliterating the nasolabial fold [Figure 1]. Skin over the swelling was normal with no visible sinus tracts. On palpation, all the inspectory findings were confirmed. The swelling was bony hard with mild tenderness and no local rise in temperature. Intraoral examination showed deficient maxilla and the absence of teeth in relation to 14–28 region [Figure 2].
|Figure 1: Extraoral photograph revealing infraorbital swelling on the left side of the face |
Click here to view
|Figure 2: Intraoral examination depicting deficient maxilla and the absence of teeth in relation to 14–28 region|
Click here to view
Computerized tomography revealed a comminuted fracture of the lateral wall of the left orbit with an asymmetric outline of the globe. The posterior wall of left orbit was also incomplete with little soft tissue masses seen protruding into its posterio-lateral aspect. Part of soft tissue was seen extending toward the anterior wall of left maxillary sinus which was completely effaced. Two metal plates were seen, supporting the anterior lateral wall of the left maxillary antrum as artifacts. These plates were presumed to be placed in the previous surgeries [Figure 3].
|Figure 3: Computerized tomography revealing comminuted fracture on lateral wall and floor of the left orbit with the tumor mass extending into the orbit|
Click here to view
On reviewing the dental history, clinical and radiological features, a provisional diagnosis of recurrent ameloblastoma of the left infraorbital region was given. The tumor was surgically excised with normal tissue margins surrounding the lesion and the excised specimen was sent for histopathological examination.
Microscopic examination revealed a nasociliary epithelium with adjacent tumor area composed of small round cells arranged in lobular pattern separated by fibrovascular stroma. These tumor cells are arranged in pseudorosettes and glandular patterns, and showed round to oval hyperchromatic nucleus with few presenting salt and pepper chromatin pattern. The adjacent bone tissue is infiltrated by these tumor cells along with new bone formation (osteoid). The stroma is fibro-cellular and -vascular with focal areas of neurofibrillary matrix, giant cells and mitoses [Figure 4].
|Figure 4: Photomicrograph showing (a) small round cells arranged in sheets and lobules (H&E stain, ×40), (b) rosettes in neurofibrillary matrix (arrow) and new bone formation (arrowhead) (H&E stain, ×100), (c) Homer wright rosettes (arrow) with central neurofibrillary matrix (H&E stain, ×400), (d) fibro-cellular and -vascular stroma (H&E stain, ×200)|
Click here to view
Based on clinical, radiological and histological findings, a final diagnosis of olfactory neuroblastoma was established. For the confirmation of the diagnosis, immunohistochemistry with a panel of markers was performed [Table 1] and [Figure 5], establishing the diagnosis as olfactory neuroblastoma. With the suspicion about the former treated pathologies, past records of the patient were reevaluated and subjected to histopathological and immunohistochemical examination. Histopathology revealed the characteristic features of olfactory neuroblastoma and was confirmed immunohistochemically with the marker neuron-specific enolase (NSE) which showed strong positivity [Figure 6]. The patient was referred to the cancer institute for adjuvant radiotherapy.
|Figure 5: Photomicrograph showing immunohistochemical staining for (a) neuron-specific enolase: strongly positive (IHC stain, x200), (b) chromogranin: positive (IHC stain, x100), (c) S-100: negative (IHC stain, x40), (d) proliferating cell nuclear antigen: positive (IHC stain, x40), (e) Ki-67: positive (labeling index: <10%) (IHC stain, x100) [Inset: showing two positive cells, (IHC stain, x400)], (f) pancytokeratins: focally positive (IHC stain, x200), (g) epithelial membrane antigen: negative (IHC stain, x100), (h) caldesmon: negative (IHC stain, x100), (i) cytokeratin-7: negative (IHC stain, x100). NSE: Neuron-specific enolase, PCNA: Proliferating cell nuclear antigen, EMA: Epithelial membrane antigen|
Click here to view
|Figure 6: Photomicrograph showing immunohistochemical staining of marker neuron-specific enolase (NSE) showing strong positivity in previously treated pathologies. (a) Section of tumor mass resected in 2007 (IHC stain, x100), (b) Section of tumor mass resected in 2013 (IHC stain, x100)|
Click here to view
| Discussion|| |
Esthesioneuroblastoma is an uncommon malignant neoplasm representing 2–3% of sinonasal tract tumors. Although there is no much evidence regarding the origin of olfactory neuroblastoma, few studies reported the possible source of this tumor to be specialized neuroectodermal olfactory cells.,, Even in the present case, there was an evidence of olfactory epithelium extending along the tumor mass. Other specific sites of origin for this tumor include Jacobson's vomeronasal organ, sphenopalatine ganglion, ectodermal olfactory placode, ganglion of Loci (nervus terminalis) and autonomic ganglia of the nasal mucosa.
Most commonly reported in all age groups with a bimodal peak in second and sixth decade with no gender predilection. In the present case, the female patient first developed tumor at an age of 16 with recurrences noticed at 22 and 24 years. The most common symptoms of olfactory neuroblastoma are nasal obstruction, epistaxis and headache. Tumors in advanced stages usually present orbital symptoms such as proptosis and excessive lacrimation, which were also noticed in the current case report.
Computed tomography (CT) provides the best information about the tumor invasion into bony structures. The CT features of olfactory neuroblastoma are nonspecific and so cannot be differentiated from other tumors such as undifferentiated lymphoma, rhabdomyosarcoma, squamous cell carcinoma, extramedullary plasmacytoma and amelanotic melanoma. Definite diagnosis is based on histopathology.
The aggressive nature of this tumor is determined by Kadish staging system, which is based on the clinical spread of the tumor [Table 2]. Moritaet al. modified Kadish staging system by incorporating Group D for tumors with regional (cervical lymph node) or distant metastases. An extensive research of previous cases of olfactory neuroblastomas revealed their presence in Kadish Stage C. The present case was also categorized under Stage C as the tumor mass was shown to be extending into the orbit. However, Kadish system could not give a definite comparison between the prognosis of surgically operable and inoperable tumors because tumors in the neck, orbit, intracranial portion and distant metastasis were all included in the same stage. Hence, histopathological grading is also mandatory to predict the treatment outcome and survival rate of this tumor.
Histopathologically, Hyams grading system  is used to differentiate low-grade (Grade 1 and 2) from high-grade tumors (Grade 3 and 4). Grading is based on few defining features of olfactory neuroblastoma such as lobular architecture, rosettes, neurofibrillary matrix, pleomorphism, mitoses, necrosis and presence of calcifications [Table 3]. Two types of rosettes are seen, of which pseudorosettes (Homer Wright rosettes) are the more common. They are characterized by a delicate neurofibrillary and edematous stroma that forms the center of a palisaded arrangement of tumor cells. True rosettes (Flexner–Wintersteiner rosettes) have a tight, “gland-like” annular arrangement. In the present case, most of the tumor cells are arranged in pseudorosette pattern in a fibro-cellular and vascular connective tissue stroma representing a stromal reaction to the proliferating tumor islands.
Histopathological evaluation of our case revealed the tumor in Hyams Grade 2, which is considered as a low-grade tumor. However, according to Kadish system, our case can be categorized as high-grade malignancy. Despite its shortcomings, Kadish system is the most commonly used classification system for olfactory neuroblastoma. The other classification systems for olfactory neuroblastoma are according to Biller et al., and Dulguerov and Calcaterra. According to Dias et al., among all classification systems, only Kadish system revealed a statistically significant discrimination among stages for relapse-free survival.
The differential diagnosis included primary intraosseous carcinoma, ameloblastic carcinoma and salivary gland carcinoma. To differentiate whether it was derived from the salivary gland epithelium, a panel of immunohistochemical markers such as epithelial membrane antigen (EMA), cytokeratin-7 (CK-7) and caldesmon was used which showed a negative staining pattern. Hence, the salivary gland tumors were ruled out. As histopathology showed nasociliary epithelium which shows olfactory neural cells, markers specific for neuroectodermal cells, such as NSE and chromogranin, were used which showed a strong positive reaction with NSE and weak positivity with chromogranin. To determine the proliferation rate, immunohistochemical staining with Ki 67 and proliferating cell nuclear antigen (PCNA) was done, which showed the labeling index of Ki 67 to be <10% and strong positivity with PCNA.
Olfactory neuroblastoma is conventionally positive for neuroendocrine markers. The most consistent marker is NSE. Other markers include synaptophysin, neurofilament protein, Class III beta-tubulin, microtubule-associated protein, chromogranin, glial fibrillary acidic protein and Leu-7. Epithelial markers such as EMA and carcinoembryonic antigen are negative. CKs are usually negative. The present case showed focal positivity for CKs which signifies that there are focal areas of epithelial differentiation which is a common feature of olfactory neuroblastoma. Caldesmon is a marker for neoplastic myoepithelial cells  and CK-7 is usually positive for salivary gland neoplasms. Their negative staining in the present case excludes the diagnosis of salivary gland carcinoma. S-100 positivity is mostly seen in the periphery, which represents the Schwann cells or sustentacular cells usually present along the periphery of neoplastic lobules. In our case, S-100 staining was negative which is a common feature seen in high-grade tumors. Ki-67 positivity showed <10% labeling index, which implies that the tumor is well differentiated and associated with long-term survival, whereas poorly differentiated (Hyams Grade 3 and 4) are associated with a high proliferation index. Majority of the features places the current case under low-grade malignancy.
An extensive search of English literature revealed a unique treatment protocol for olfactory neuroblastoma. A combined treatment of surgery and radiation therapy (RT) resulted in a better recurrence -free rate (60–100%) compared with surgery alone (14–56%). Lund et al. considered the above combination as the gold standard treatment. In the present case, as the tumor was extended into the orbit (Kadish Stage C) and as the tumor recurred thrice, aggressive surgical excision with adjuvant radiotherapy is the mainstay of treatment.
Elkon included the presence of metastasis and local extension of the tumor (e.g. ethmoidal, nasopharynx, orbital) as negative prognostic factors. Dulguerov and Calcaterra considered tumor recurrence and metastases as significant negative prognostic factors.
| Conclusion|| |
Olfactory neuroblastoma is a rare malignant tumor with varied clinical behavior. A proper diagnosis should be made through clinical, radiographic and histopathological findings and the tumor should be staged and graded before proceeding to surgery. Aggressive surgical resection and RT is the mainstay of treatment and patients must be followed up carefully as local or regional recurrences are most commonly associated.
- Dr. Radhika M Bavle, MDS, Professor and Head of the Department of Oral pathology, Krishnadevaraya College of Dental Sciences and Hospital, Bangalore, Karnataka
- Dr. Varsha Jadhav, MD, Department of General Pathology, Mamata Medical College, Khammam, Telangana.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Berger L, Luc R, Richard D. The 'esthesioneur olfactory epithelium. Fr Bull Assoc Cancer Study 1924;13:410-21.
Ghaffar S, Salahuddin I. Olfactory neuroblastoma: A case report and review of the literature. Ear Nose Throat J 2005;84:150-2.
Unger F, Haselsberger K, Walch C, Stammberger H, Papaefthymiou G. Combined endoscopic surgery and radiosurgery as treatment modality for olfactory neuroblastoma (esthesioneuroblastoma). Acta Neurochir (Wien) 2005;147:595-601.
Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: A general review of the cases published since the discovery of the tumour in 1924. Anticancer Res 1997;17:2683-706.
Banerjee AK, Sharma BS, Vashista RK, Kak VK. Intracranial olfactory neuroblastoma: Evidence for olfactory epithelial origin. J Clin Pathol 1992;45:299-302.
Hassoun J, Gambarelli D, Grisoli F, Henric A, Toga M. Esthesioneuroepithelioma, a true neurosensorial tumor. Light- and electron-microscopic study of a case with endocranial extension. Acta Neuropathol 1981;55:77-80.
Takahashi H, Ohara S, Yamada M, Ikuta F, Tanimura K, Honda Y. Esthesioneuroepithelioma: A tumor of true olfactory epithelium origin. An ultrastructural and immunohistochemical study. Acta Neuropathol 1987;75:147-55.
Thompson LD. Olfactory neuroblastoma. Head Neck Pathol 2009;3:252-9.
Rosai J. Respiratory tract. In: Ackerman's Surgical Pathology. 9th
ed., Vol. 1., St. Louis, MO, USA: Elsevier Mosby; 2004. p. 316-7.
Pickuth D, Heywang-Köbrunner SH, Spielmann RP. Computed tomography and magnetic resonance imaging features of olfactory neuroblastoma: An analysis of 22 cases. Clin Otolaryngol Allied Sci 1999;24:457-61.
Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer 1976;37:1571-6.
Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: Prognosis and management. Neurosurgery 1993;32:706-14.
Song CM, Won TB, Lee CH, Kim DY, Rhee CS. Treatment modalities and outcomes of olfactory neuroblastoma. Laryngoscope 2012;122:2389-95.
Hyams VJ. Tumours of the upper respiratory tract and ear. In: Hyams VJ, Batsakis JG, Michaels L, editors. Atlas of Tumour Pathology. 2nd
Series, Fascicle 25. Washington: Armed Forces Institute of Pathology; 1988, p. 240-8.
Biller HF, Lawson W, Sachdev VP, Som P. Esthesioneuroblastoma: Surgical treatment without radiation. Laryngoscope 1990;100:1199-201.
Dulguerov P, Calcaterra T. Esthesioneuroblastoma: The UCLA experience 1970-1990. Laryngoscope 1992;102:843-9.
Dias FL, Sa GM, Lima RA, Kligerman J, Leoncio MP, Freitas EQ, et al.
Patterns of failure and outcome in esthesioneuroblastoma. Arch Otolaryngol Head Neck Surg 2003;129:1186-92.
Zarbo RJ, Torres FX, Gomez J. Nasal cavity and paranasal sinuses. In: PilchBZ, editors. Head and neck surgical pathology. Philadelphia: Lippincott Williams & Wilkins; 2001, p. 127.
Barnes L, Eveson JW, Reichart P, Sidransky D. WHO Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. Lyon: IARC Press; 2005, p. 68.
Nagao T, Sato E, Inoue R, Oshiro H, H Takahashi R, Nagai T, et al.
Immunohistochemical analysis of salivary gland tumors: Application for surgical pathology practice. Acta Histochem Cytochem 2012;45:269-82.
Meer S, Altini M. CK7+/CK20- immunoexpression profile is typical of salivary gland neoplasia. Histopathology 2007;51:26-32.
Eriksen JG, Bastholt L, Krogdahl AS, Hansen O, Joergensen KE. Esthesioneuroblastoma – What is the optimal treatment? Acta Oncol 2000;39:231-5.
Lund VJ, Howard D, Wei W, Spittle M. Olfactory neuroblastoma: Past, present, and future? Laryngoscope 2003;113:502-7.
Homzie MJ, Elkon D. Olfactory esthesioneuroblastoma – Variables predictive of tumor control and recurrence. Cancer 1980;46:2509-13.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6]
[Table 1], [Table 2], [Table 3]